Kvk Tech Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for KVK TECH, and when can generic versions of KVK TECH drugs launch?
KVK TECH has thirteen approved drugs.
There are five US patents protecting KVK TECH drugs.
There are thirty-five patent family members on KVK TECH drugs in twenty countries and sixty-one supplementary protection certificates in eight countries.
Summary for Kvk Tech
| International Patents: | 35 |
| US Patents: | 5 |
| Tradenames: | 9 |
| Ingredients: | 9 |
| NDAs: | 13 |
Drugs and US Patents for Kvk Tech
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kvk Tech Inc | APADAZ | acetaminophen; benzhydrocodone hydrochloride | TABLET;ORAL | 208653-001 | Feb 23, 2018 | RX | Yes | No | 9,549,923 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Kvk Tech Inc | APADAZ | acetaminophen; benzhydrocodone hydrochloride | TABLET;ORAL | 208653-003 | Jan 4, 2019 | RX | Yes | Yes | 8,828,978 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Kvk Tech | HYDROXYZINE HYDROCHLORIDE | hydroxyzine hydrochloride | TABLET;ORAL | 040786-001 | Mar 20, 2007 | AB | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Kvk Tech Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 101971223 | See Plans and Pricing |
| South Korea | 20190042115 | See Plans and Pricing |
| Costa Rica | 20110688 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Kvk Tech Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1948158 | 16C0018 | France | See Plans and Pricing | PRODUCT NAME: SACUBITRIL/VALSARTAN,SOUS FORME DE COMPLEXE SODIQUE SACUBITRIL VALSARTAN,C'EST-A-DIRE DE (3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL) PROPIONATE-(S)-3'-METHYL-2'-(PENTANOY(2''-(TETRAZOL-5-YLATE)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRATE)DE TRISODIUM HEMIPENTAHYDRATE; REGISTRATION NO/DATE: EU/1/15/1058 20151123 |
| 2932970 | SPC/GB18/041 | United Kingdom | See Plans and Pricing | PRODUCT NAME: A COMBINATION COMPRISING DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. DOLUTEGRAVIR SODIUM) AND RILPIVIRINE OR A PHARAMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. RILPIVIRINE HYDROCHLORIDE); REGISTERED: UK EU/1/18/1282 20180518; UK PLGB 35728/0055 20180518; UK PLGB 35728/0056 20180518; UK PLGB 35728/0057 20180518 |
| 2666774 | LUC00167 | Luxembourg | See Plans and Pricing | PRODUCT NAME: RELEBACTAM, EVENTUELLEMENT SOUS FORME DE MONOHYDRATE, IMIPENEME ET CILASTATINE, EVENTUELLEMENT SOUS FORME DE SEL DE SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/19/1420 20200217 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
